Post-transplant lymphoproliferative disease

Common Name(s)

Post-transplant lymphoproliferative disease

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Post-transplant lymphoproliferative disease" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Post-transplant lymphoproliferative disease" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Post-transplant lymphoproliferative disease" returned 16 free, full-text research articles on human participants. First 3 results:

Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation.
 

Author(s): Michael Uhlin, Helena Wikell, Mikael Sundin, Ola Blennow, Markus Maeurer, Olle Ringden, Jacek Winiarski, Per Ljungman, Mats Remberger, Jonas Mattsson

Journal: Haematologica. 2014 Feb;99(2):346-52.

 

Allogeneic hematopoietic stem cell transplantation is a successful treatment for hematologic malignancies and a variety of genetic and metabolic disorders. In the period following stem cell transplantation, the immune-compromised milieu allows opportunistic pathogens to thrive. Epstein-Barr ...

Last Updated: 5 Feb 2014

Go To URL
Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8 cases.
 

Author(s): Ralf Trappe, Heiner Zimmermann, Susanne Fink, Petra Reinke, Martin Dreyling, Andreas Pascher, Hans Lehmkuhl, Barbara Gärtner, Ioannis Anagnostopoulos, Hanno Riess

Journal: Haematologica. 2011 Jul;96(7):1067-71.

 

Post-transplantation lymphoproliferative disorder (PTLD) with plasmacellular differentiation has been reported as a rare subtype of monomorphic B-cell post-transplant lympho-proliferation with histological and immunophenotypical features of plasmacytoma in the non-transplant population. ...

Last Updated: 1 Jul 2011

Go To URL
Tumour necrosis factor gene polymorphism: a predictive factor for the development of post-transplant lymphoproliferative disease.
 

Author(s): K A McAulay, T Haque, D H Crawford

Journal: Br. J. Cancer. 2009 Sep;101(6):1019-27.

 

Epstein-Barr virus-positive post-transplant lymphoproliferative disease (PTLD) is a potentially lethal complication of iatrogenic immunosupression after transplantation. Predicting the development of PTLD allowing early and effective intervention is therefore of importance. Polymorphisms ...

Last Updated: 9 Sep 2009

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Post-transplant lymphoproliferative disease" returned 3 free, full-text review articles on human participants. First 3 results:

T-cell therapy in the treatment of post-transplant lymphoproliferative disease.
 

Author(s): Catherine M Bollard, Cliona M Rooney, Helen E Heslop

Journal: Nat Rev Clin Oncol. 2012 Sep;9(9):510-9.

 

Post-transplant lymphoproliferative diseases (PTLD) associated with Epstein-Barr virus (EBV) infection often develop after organ and haematopoietic stem-cell transplantation. These lymphoproliferative diseases are tumours that usually express all latent EBV viral proteins, and are ...

Last Updated: 29 Aug 2012

Go To URL
Post-transplant lymphoproliferative disorder in view of the new WHO classification: a more rational approach to a protean disease?
 

Author(s): Krzysztof Mucha, Bartosz Foroncewicz, Bogna Ziarkiewicz-Wróblewska, Marek Krawczyk, Jan Lerut, Leszek Paczek

Journal: Nephrol. Dial. Transplant.. 2010 Jul;25(7):2089-98.

 

Post-transplant lymphoproliferative disorders (PTLDs) are serious, life-threatening complications of solid-organ transplantation (SOT) and bone marrow transplantation leading to a high mortality (30-60%). PTLD represents a heterogeneous group of lymphoproliferative diseases. They ...

Last Updated: 25 Jun 2010

Go To URL
Management of Epstein-Barr virus-induced post-transplant lymphoproliferative disease in recipients of solid organ transplantation.
 

Author(s): M Green

Journal: Am. J. Transplant.. 2001 Jul;1(2):103-8.

 

The optimal management of Epstein-Barr virus (EBV)-induced post-transplant lymphoproliferative diseases (PTLD) remains controversial. While withdrawal or reduction of immunosuppression is widely accepted as the strategy for the treatment of EBV/PTLD, the role of additional therapeutic ...

Last Updated: 8 Jul 2002

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Bortezomib Plus Rituximab for EBV+ PTLD
 

Status: Recruiting

Condition Summary: Post-transplant Lymphoproliferative Disease; Solid Organ Transplant; Stem Cell Transplant (Bone Marrow Transplant); Epstein Barr Virus Infections

 

Last Updated: 16 May 2014

Go to URL
Phase II of Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma
 

Status: Recruiting

Condition Summary: Epstein Barr Virus Associated Non Hodgkin's Lymphoma; Epstein Barr Virus Associated Hodgkin's Lymphoma; Post-Transplant Lymphoproliferative Disease

 

Last Updated: 23 Apr 2014

Go to URL
Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy
 

Status: Not yet recruiting

Condition Summary: Posttransplant Lymphoproliferative Disorder

 

Last Updated: 25 Apr 2014

Go to URL